Rapport Therapeutics (NASDAQ:RAPP) Shares Down 6.9% – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP)’s share price fell 6.9% during mid-day trading on Friday . The stock traded as low as $15.07 and last traded at $15.54. 33,377 shares were traded during mid-day trading, a decline of 52% from the average session volume of 69,255 shares. The stock had previously closed at $16.69.

Rapport Therapeutics Stock Down 7.2 %

The firm’s 50-day simple moving average is $20.85.

Institutional Trading of Rapport Therapeutics

A number of hedge funds have recently modified their holdings of the business. Values First Advisors Inc. acquired a new stake in Rapport Therapeutics during the 3rd quarter worth about $31,000. BNP Paribas Financial Markets bought a new position in Rapport Therapeutics during the third quarter valued at approximately $34,000. JPMorgan Chase & Co. acquired a new stake in Rapport Therapeutics in the third quarter valued at approximately $83,000. SG Americas Securities LLC bought a new stake in Rapport Therapeutics in the third quarter worth approximately $101,000. Finally, Sandia Investment Management LP acquired a new position in shares of Rapport Therapeutics during the 2nd quarter worth $116,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.